Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium, Portola deal

Portola licensed exclusive worldwide rights to MLNM's Factor Xa inhibitor program to treat thrombosis. MLNM

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE